Clinical usefulness of recombinant activated factor VII in patients with liver failure undergoing invasive procedures;Utilidad Clínica del Factor VII Activado Recombinante en Pacientes con Insuficiencia Hepática que Van a Someterse a Técnicas Invasivas

Annals of Pharmacotherapy

Volumn 45, Issue 11, 2011, Pages 1433-1438

  Krisl, Jill C ^a   Meadows, Holly E ^a   Greenberg, Charles S ^a   Mazur, Joseph E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute liver failure; Chronic liver failure; Coagulopathy; Recombinant activated factor VII

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP;

ACUTE LIVER FAILURE; ARTICLE; CHRONIC LIVER FAILURE; COLONOSCOPY; DENTAL SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; FIBRIN DEPOSITION; FULMINANT HEPATIC FAILURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL PRESSURE MONITORING; INVASIVE PROCEDURE; LIVER BIOPSY; LIVER RESECTION; LIVER TRANSPLANTATION; PANCREAS BIOPSY; PARTIAL THROMBOPLASTIN TIME; PERICARDIOCENTESIS; POLYPECTOMY; PRIORITY JOURNAL; PROTHROMBIN TIME; TREATMENT DURATION;

FACTOR VIIA; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; PROSPECTIVE STUDIES; PROTHROMBIN TIME; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 80155190188     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q207     Document Type: Article

References (24)

1. Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010;53: 362-71. DOI 10.1016/j.jhep.2010.01.042
2. Northup PG. Hypercoagulation in liver disease. Clin Liver Dis 2009;13: 109-16. DOI 10.1016/j.cld.2008.09.003
3. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002;22:83-96. DOI 10.1055/s-2002-23205
4. Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis 2009;13:95-107. DOI 10.1016/j.cld.2008.10.001
5. Mahajan A, Lat I. Correction of coagulopathy in the setting of acute liver failure. Crit Care Nurs Clin North Am 2010;22:315-21. DOI 10.1016/j.ccell.2010.02.001
6. Franchini M, Montagnana M, Targher G, et al. The use of recombinant factor VIIa in liver disease. Blood Coagul Fibrinolysis 2008;19:341-8. DOI 10.1097/MBC.0b013e32830496a7
7. Blonski W, Siropaides T, Reddy KR. Coagulopathy in liver disease. Curr Treat Options Gastroenterol 2007;10:464-73.
8. Shah NL, Caldwell SH, Berg CL. The role of anti-fibrinolytics, rFVIIa, and other pro-coagulants: prophylactic versus rescue? Clin Liver Dis 2009;13:87-93. DOI 10.1016/j.cld.2008.09.005
9. Shander A, Goodnough LT, Ratko TR, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. P&T 2005;30:644-58.
10. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930-7.
11. Jeffers L, Chalasani N, Balart L, et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002;123:118-26.
12. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminate hepatic failure compared with conventional therapy. Liver Transpl 2003;9:138-43. DOI 10.1053/jlts.2003.50017
13. Ananthabaju A, Mehta K, Mindikoglu AL, Van Thiel DH. Use of activated recombinant human factor VII (rhFVIIa) for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci 2003; 48:1414-24.
14. Mindikoglu AL, Ananthabaju A, Villanueva J, et al. Pericardiocentesis and pancreatic aspiration needle biopsy in coagulopathic and thrombocytopenic cirrhotic patient. Chest 2003;123:956-8.
15. Tsochatzis E, Papatheodoridis GV, Elefsiniotis I, et al. Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. Dig Liver Dis 2007;39:490-4. DOI 10.1016/j.dld.2006.05.015
16. Sobhi EA. Successful outcome of using recombinant activated factor VII (rFVIIa) in liver biopsy in a patient with liver failure. J Thromb Haemost 2006;4:2073-4.
17. Shao YF, Yang JM, Chau GY, et al. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 2006;191:245-9. DOI 10.1016/j.amjsurg.2005.10.019
18. Sajjad S, Garcia M, Malik A, et al. Use of recombinant factor VIIa to correct the coagulation status of individuals with advanced liver disease prior to a percutaneous liver biopsy. Dig Dis Sci 2009;54:1115-9. DOI 10.1007/s10620-009-0753-0
19. Le TV, Rumbak MJ, Liu SS, et al. Insertion of intracranial pressure monitors in fulminant hepatic failure patients: early experience using recombinant factor VII. Neurosurgery 2010;66:455-8. DOI 10.1227/0.1.neu.0000365517.52586.A2
20. Tonda R, Galán AM, Pino M, Cirera I, et al. Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. J Hepatol 2003;39:954-9.
21. Mehta AB. Management of coagulopathy in patients with liver disease undergoing surgical intervention. Indian J Gastroenterol 2006;25:S19-21.
22. Brown JB, Emerick KM, Brown DL, et al. Recombinant factor VIIa im-proves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003;37:268-72.
23. Product information. NovoSeven (recombinant coagulation factor VIIa). Princeton, NJ: NovoNordisk, August 2010.
24. Akyildiz M, Turan I, Ozutemiz O, et al. A cerebrovascular event after single-dose administration of recombinant factor VIIa in a patient with esophageal variceal bleeding. Dig Dis Sci 2006;51:1647-9. DOI 10.1007/s10620-005-9023-y